13. (Note: subjects with a venous filter (e.g. vena cava filter) are not eligible for this study) b. Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: i. Any of the following within 28 days before the first dose of study treatment • intra-abdominal tumor/metastases invading GI mucosa • active peptic ulcer disease; patients must be completely recovered • inflammatory bowel disease (including ulcerative colitis and Crohn's disease), acute pancreatitis, pancreatic duct or common bile duct obstruction, acute diverticulitis, acute cholecystitis, symptomatic cholangitis or recent appendicitis within 1 month of first dose of cabozantinib; patients must be completely recovered from these conditions • clinically significant malabsorption syndrome, c. Endocrine disorders, uncontrolled Cushing syndrome despite of adequate medical therapy